It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the year.

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. | ...

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

Just two weeks into 2025, January is proving why it’s earned a reputation as the worst month for layoffs. | Just two weeks ...

4D Molecular Therapeutics is axing two clinical programs and cutting off funds for three other assets, with resources to be ...

A new company is making its debut with a series A sum that’s sure to make hearts race. | A new company is making its debut ...

Eli Lilly and venture capital firm Andreessen Horowitz (a16z) are joining forces to create a unique new fund dubbed the ...

The neuromodulation developer Saluda Medical announced that it raised $100 million to help bolster the sales of its ...

The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma ...

Windward Bio has landed with a flurry of announcements, circling in a $200 million series A and offering up to $970 million ...